Analysts at StockNews.com assumed coverage on shares of Navidea Biopharmaceuticals (NYSE:NAVB – Get Free Report) in a research note issued to investors on Saturday. The firm set a “sell” rating on the stock.
Navidea Biopharmaceuticals Stock Performance
Shares of NAVB opened at $0.00 on Friday. The stock has a market capitalization of $100,084.00, a P/E ratio of -0.02 and a beta of 1.47. Navidea Biopharmaceuticals has a 12-month low of $0.00 and a 12-month high of $0.10.
Navidea Biopharmaceuticals Company Profile
See Also
- Five stocks we like better than Navidea Biopharmaceuticals
- What Does Downgrade Mean in Investing?
- Can Costco Stock Hit New Highs as Interest Rates Drop?
- Best Stocks Under $5.00
- These 3 Stocks Show How to Navigate Declining Consumer Confidence
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- MicroStrategy’s Returns Are 3X Higher Than Bitcoin: Time to Buy?
Receive News & Ratings for Navidea Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Navidea Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.